`
`A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
`
`Latest version (submitted January 12, 2012) on ClinicalTrials.gov
`
`A study version is represented by a row in the table.
`
`Select two study versions to compare. One each from columns A and B.
`
`Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only
`applies to the Protocol section of the study.
`
`Click "Compare" to do the comparison and show the differences.
`
`Select a version's Submitted Date link to see a rendering of the study for that version.
`
`The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
`
`Hover over the "Recruitment Status" to see how the study's recruitment status changed.
`
`Study edits or deletions are displayed in red .
`
`Study additions are displayed in green .
`
`Study Record Versions
`
`Version
`
`A
`
`B
`
`Submitted Date
`
`Changes
`
`1
`
`2
`
`3
`
`June 21, 2010 None (earliest Version on record)
`
`June 22, 2010 Sponsor/Collaborators and Study Status
`
`July 8, 2010 Recruitment Status, Study Status and Contacts/Locations
`
`Exhibit 2054
`Page 01 of 08
`
`
`
`Version
`
`A
`
`B
`
`Submitted Date
`
`Changes
`
`4
`
`5
`
`6
`
`7
`
`8
`
`August 24, 2010 Contacts/Locations and Study Status
`
`September 10, 2010 Study Status and Study Identification
`
`March 14, 2011 Contacts/Locations, Study Status and Sponsor/Collaborators
`
`October 3, 2011 Study Status and Sponsor/Collaborators
`
`January 12, 2012 Recruitment Status, Study Status, Contacts/Locations and Study Design
`
`Compare
`
` Comparison Format:
`
` Merged
` Side-by-Side
`
`Scroll up to access the controls
`
`Study NCT01148615
`Submitted Date: June 21, 2010 (v1)
`
` Study Identification
`
`Unique Protocol ID: TCD11382
`
`Brief Title: A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
`
`Official Title: A Phase I, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous
`Aflibercept in Combination With Intravenous Docetaxel Administrated Every 3 Weeks in Chinese Patients
`With Advanced Solid Malignancies
`
`Secondary IDs:
`
`Exhibit 2054
`Page 02 of 08
`
`
`
` Study Status
`
`Record Verification: June 2010
`
`Overall Status: Not yet recruiting
`
`Study Start: July 2010
`
`Primary Completion: July 2011 [Anticipated]
`
`Study Completion: January 2012 [Anticipated]
`
`First Submitted: June 21, 2010
`
`June 21, 2010
`
`First Submitted that
`Met QC Criteria:
`First Posted: June 22, 2010 [Estimate]
`
`Last Update Submitted that
`Met QC Criteria:
`Last Update Posted: June 22, 2010 [Estimate]
`
`June 21, 2010
`
` Sponsor/Collaborators
`
`Sponsor: Sanofi
`
`Responsible Party:
`
`Collaborators:
`
`Exhibit 2054
`Page 03 of 08
`
`
`
` Oversight
`
`U.S. FDA-regulated Drug:
`
`U.S. FDA-regulated Device:
`
`Data Monitoring: No
`
` Study Description
`
`Brief Summary: Primary Objective:
`
`To confirm the dose of aflibercept in western studies by assessing the dose-limiting toxicity (DLT) of
`intravenous (IV) aflibercept when administered in combination with docetaxel given intravenously
`every 3 weeks in Chinese patients with solid tumors.
`
`Secondary Objectives:
`
`To assess the safety profile of intravenous (IV) aflibercept when administered in combination with
`docetaxel
`To determine the pharmacokinetics of IV aflibercept and docetaxel when administered in
`combination
`To make a preliminary assessment of antitumor effects of the combination of docetaxel plus
`aflibercept in patients with evaluable disease
`To evaluate the immunogenicity of IV aflibercept
`To measure endogenous free Vascular Endothelial Growth Factor (VEGF)
`
`Detailed Description: The duration of screening, treatment, and follow-up are within 21 days, 3 weeks/cycle, and 90 days after
`the last aflibercept administration. Patients will be administered aflibercept in combination with docetaxel
`until when/if a definitive treatment discontinuation criterion is met such as progressive disease,
`unacceptable toxicity or patient refusal to continue.
`
`Exhibit 2054
`Page 04 of 08
`
`
`
` Conditions
`
` Study Design
`
`Conditions: Neoplasm Malignant
`
`Keywords:
`
`Study Type: Interventional
`
`Primary Purpose: Treatment
`
`Study Phase: Phase 1
`
`Interventional Study Model: Single Group Assignment
`
`Number of Arms: 1
`
`Masking: None (Open Label)
`
`Allocation: N/A
`
`Enrollment: 22 [Anticipated]
`
` Arms and Interventions
`
`Arms
`
`Experimental: Aflibercept/ docetaxel
`Patients with advanced cancer will receive different doses of aflibercept in
`combination with approved dose of docetaxel.
`Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel
`75mg/m2 IV over 1 hour on Day 1, every 3 weeks
`
`Assigned Interventions
`Drug: Aflibercept (AVE0005)
`Pharmaceutical form: solution for infusion
`Route of administration: intravenous
`Drug: Docetaxel (XRP6976)
`Pharmaceutical form: solution for infusion
`Route of administration: intravenous
`
`Exhibit 2054
`Page 05 of 08
`
`
`
` Outcome Measures
`
`Primary Outcome Measures:
`
`1. Dose-Limiting Toxicity (DLT)
`[ Time Frame: 3 weeks (cycle 1) ]
`
`
`Secondary Outcome Measures:
`
`1. Global safety profile based on treatment emergent adverse events, serious adverse events, and
`laboratory abnormalities
`[ Time Frame: Up to 30 days after last administration within a maximum follow up of 18 months ]
`
`2. Pharmacokinetic parameters of aflibercept
`[ Time Frame: up to last aflibercept administration +90 days ]
`
`
`3. Pharmacokinetic parameters of docetaxel
`[ Time Frame: cycle 1 ]
`
`
`4. Tumor response rate as calculated by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
`[ Time Frame: up to a maximum follow-up of 18 months ]
`
`
`5. Immunogenicity of Aflibercept
`[ Time Frame: up to last aflibercept administration+90 days ]
`
`
`6. Endogenous free VEGF
`[ Time Frame: up to last aflibercept administration+30 days ]
`
`
`Exhibit 2054
`Page 06 of 08
`
`
`
` Eligibility
`
`Minimum Age: 18 Years
`
`Maximum Age:
`
`Sex: All
`
`Gender Based:
`
`Accepts Healthy Volunteers: No
`
`Criteria: Inclusion criteria :
`
`Histologically or cytologically confirmed solid malignancy that metastatic or unresectable for which
`standard curative measures do not exist, but for which docetaxel treatment is appropriate.
`
`Exclusion criteria :
`
`Squamous histology/cytology lung cancer
`Need for a major surgical procedure or radiation therapy during the study
`Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an investigational agent
`within 28 days
`Cumulative radiation therapy to >25% of the total bone marrow
`History of brain metastases
`Eastern Cooperative Oncology Group(ECOG)>1
`Prior docetaxel treatment but have not been appropriate for safety reasons
`Inadequate organ and bone marrow function
`Uncontrolled hypertension
`Evidence of clinically significant bleeding diathesis or underlying coagulopathy
`
`The above information is not intended to contain all considerations relevant to a patient's potential
`participation in a clinical trial.
`
`Exhibit 2054
`Page 07 of 08
`
`
`
` Contacts/Locations
`
`Central Contact Person: Public Registry ICD
`Email: GV-Contact-us@sanofi-aventis.com
`Study Officials: International Clinical Development Study Director
`Study Director
`Sanofi
`
`Locations:
`
` IPDSharing
`
`Plan to Share IPD:
`
` References
`
`Links:
`
`Available IPD/Information:
`
`Scroll up to access the controls
`
`Scroll to the Study top
`
`U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services
`
`Exhibit 2054
`Page 08 of 08
`
`